Drug Information

Drug General Information
Drug ID
D0P0ZY
Former ID
DNCL003131
Drug Name
Pomaglumetad
Indication Schizophrenia [ICD9: 295; ICD10:F20] Phase 1 [523714]
Company
Eli Lilly
Target and Pathway
Target(s) Metabotropic glutamate receptor3 Target Info Modulator [530986]
Metabotropic glutamate receptor 2 Target Info Modulator [530986]
KEGG Pathway Neuroactive ligand-receptor interaction
Glutamatergic synapse
Cocaine addictionhsa04080:Neuroactive ligand-receptor interaction
Cocaine addiction
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Ionotropic glutamate receptor pathway
Metabotropic glutamate receptor group II pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Metabotropic glutamate receptor group II pathway
Reactome G alpha (i) signalling events
Class C/3 (Metabotropic glutamate/pheromone receptors)R-HSA-418594:G alpha (i) signalling events
Class C/3 (Metabotropic glutamate/pheromone receptors)
WikiPathways GPCRs, Class C Metabotropic glutamate, pheromone
GPCR ligand binding
GPCR downstream signalingWP501:GPCRs, Class C Metabotropic glutamate, pheromone
GPCR downstream signaling
References
Ref 523714ClinicalTrials.gov (NCT01487083) A Long-Term Study in Schizophrenia. U.S. National Institutes of Health.
Ref 530986LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul;11(7):833-45.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.